COLUMBIA, Md. - Marylandian -- Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.

Precision Antibody will attend the partnering-focused meeting alongside A&G Pharmaceutical, Inc., engaging with biopharmaceutical companies, investors, and research leaders to explore strategic collaborations in targeted therapies and antibody-based drug development.

The Targeted Therapies Licensing & Partnering Summit Asia is a premier event designed to facilitate high-value business development discussions, licensing opportunities, and cross-border partnerships within oncology and precision medicine. The summit provides a dedicated platform for companies advancing innovative therapeutic assets to connect with potential partners across Asia and globally.

More on Marylandian

• PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
• Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
• From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
• Now Live on Kickstarter: The Bottle That Chills and Purifies Any Freshwater — and Donates One for Every 10 Backers
• How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment

Precision Antibody brings to the meeting its extensive expertise in custom monoclonal antibody development, including fully human antibody generation and biomarker-focused antibody solutions that support therapeutic and translational research initiatives.

"Partnering meetings like this play a critical role in accelerating innovation," said Dr. Serrero. "We look forward to engaging with potential collaborators in Tokyo and exploring opportunities to advance targeted therapy programs through strategic partnerships."

As biomarker antibody specialists, Precision Antibody has established a strong track record in developing high-quality, high-affinity monoclonal antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

More on Marylandian

• Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
• Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
• Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
• NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
• Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches

Through its collaboration-driven approach and commitment to scientific excellence, Precision Antibody continues to support biopharma partners in accelerating the discovery and development of next-generation targeted therapeutics.

Attendees of the Targeted Therapies Licensing & Partnering Summit Asia 2026 are invited to connect with representatives from Precision Antibody and A&G Pharmaceutical to discuss licensing opportunities, co-development partnerships, and strategic collaborations.

Event Details:

Targeted Therapies Licensing & Partnering Summit Asia 2026
Dates: February 26–27, 2026
Location: Meguro-ku, Tokyo, Japan
Event Website: https://targeted-therapies-asia.com/